Dhital Kumud, Ludhani Prakash, Scheuer Sarah, Connellan Mark, Macdonald Peter
Department of Cardiothoracic Surgery & Transplantation, Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004 Australia.
Transplant Laboratory, Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool St, Darlinghurst, NSW 2010 Australia.
Indian J Thorac Cardiovasc Surg. 2020 Aug;36(Suppl 2):224-232. doi: 10.1007/s12055-020-00998-x. Epub 2020 Aug 15.
There is increasing clinical utilization of hearts from the donation after circulatory death (DCD) pathway with the aim of expanding the donor pool and mitigating the ever-present discrepancy between the inadequate availability of good quality donor hearts and the rising number of patients with end-stage heart failure.
This article reviews the rationale, practice, logistical factors, and 5-year experience of DCD heart transplantation at St Vincent's Hospital, Sydney.
Between July 2014 and July 2019, 69 DCD donor retrievals were undertaken resulting in 49 hearts being instrumented on an ex situ normothermic cardiac perfusion device. Seventeen (35%) of these hearts were declined and the remaining 32 (65%) were used for orthotopic DCD heart transplantation. At 5 years of follow-up, the 1-, 3-, and 5-year survival was 96%, 94%, and 94% for DCD hearts compared with 89%, 83%, and 82% respectively for donation after brain death (DBD) hearts (n.s). The immediate post-implant requirement for temporary extra-corporeal membrane oxygenation (ECMO) support for delayed graft function was 31% with no difference in rejection rates when compared with the contemporaneous cohort of patients transplanted with standard criteria DBD hearts.
DCD heart transplantation has become routine and incorporated into standard clinical practice by a handful of pioneering clinical transplant centres. The Australian experience demonstrates that excellent medium-term outcomes are achievable from the use of DCD hearts. These outcomes are consistent across the other centres and consequently favour a more rapid and wider uptake of heart transplantation using DCD donor hearts, which would otherwise be discarded.
为了扩大供体库,并缓解优质供体心脏供应不足与晚期心力衰竭患者数量不断增加之间一直存在的差距,循环死亡后器官捐献(DCD)途径的心脏在临床上的应用日益增多。
本文回顾了悉尼圣文森特医院进行DCD心脏移植的基本原理、实践、后勤因素及5年经验。
2014年7月至2019年7月期间,共进行了69例DCD供体心脏获取,其中49颗心脏被置于体外常温心脏灌注装置上。这些心脏中有17颗(35%)被拒收,其余32颗(65%)用于原位DCD心脏移植。在5年随访中,DCD心脏的1年、3年和5年生存率分别为96%、94%和94%,而脑死亡后器官捐献(DBD)心脏的相应生存率分别为89%、83%和82%(无统计学差异)。因移植心功能延迟而在植入后立即需要临时体外膜肺氧合(ECMO)支持的比例为31%,与同期接受标准标准DBD心脏移植的患者队列相比,排斥率无差异。
DCD心脏移植已成为常规手术,并被少数开拓性临床移植中心纳入标准临床实践。澳大利亚的经验表明,使用DCD心脏可取得出色的中期结果。这些结果在其他中心也是一致的,因此有利于更快、更广泛地采用使用DCD供体心脏的心脏移植,否则这些心脏将被丢弃。